Topic: Continuous Renal Replacement Therapy

---

Disclaimer: This information is intended for educational purposes only and should not be considered medical advice. It is crucial for healthcare professionals to exercise their clinical judgment, consult primary literature, and adhere to local institutional guidelines when making patient care decisions. The field of medicine is constantly evolving, and this content may not reflect the absolute latest developments.

---

Continuous Renal Replacement Therapy

Overview

• Definition: Continuous Renal Replacement Therapy (CRRT) is a group of extracorporeal blood purification therapies used for critically ill patients with acute kidney injury (AKI) and/or severe fluid overload. Unlike intermittent hemodialysis (IHD), CRRT provides a slower, continuous, and more gentle removal of fluids and solutes over 24 hours, which is better tolerated hemodynamically in unstable patients.
• Epidemiology: AKI affects a significant portion of critically ill patients (up to 50%), with 5-10% of these requiring renal replacement therapy (RRT). CRRT is the preferred modality for RRT in the majority of hemodynamically unstable intensive care unit (ICU) patients, particularly those with sepsis, cardiogenic shock, or multiple organ dysfunction syndrome (MODS).
• Classification: CRRT modalities are primarily distinguished by the mechanism of solute removal:
  • Slow Continuous Ultrafiltration (SCUF): Primarily fluid removal via ultrafiltration (convection) with minimal solute clearance. Used for fluid overload in hemodynamically unstable patients who do not require significant solute removal.
  • Continuous Veno-Venous Hemofiltration (CVVH): Solute and fluid removal primarily by convection. Blood passes through a highly permeable membrane, and large volumes of a replacement fluid are infused pre- or post-filter to "drag" solutes and water across the membrane.
  • Continuous Veno-Venous Hemodialysis (CVVHD): Solute removal primarily by diffusion. Blood flows on one side of a semipermeable membrane, and dialysate solution flows counter-current on the other side, creating a concentration gradient for solute diffusion. Fluid removal is achieved by ultrafiltration.
  • Continuous Veno-Venous Hemodiafiltration (CVVHDF): Combines both diffusion and convection for solute removal, offering efficient clearance of both small and middle-sized molecules. It utilizes both dialysate flow (diffusion) and replacement fluid flow (convection).

Pathophysiology (Mechanism of Action)

• Mechanism:
  • Diffusion: Solute movement across a semipermeable membrane down a concentration gradient. This is the primary mechanism in CVVHD, where dialysate fluid flows counter-current to blood. Effective for small molecule clearance (e.g., urea, creatinine, electrolytes).
  • Convection (Solvent Drag): Solute movement across a semipermeable membrane along with the movement of water (solvent). This is achieved by creating a transmembrane pressure gradient, forcing plasma water (ultrafiltrate) and dissolved solutes through the membrane. Primary mechanism in CVVH, effective for both small and middle molecules.
  • Ultrafiltration: The process of removing excess plasma water from the blood across the filter membrane. This rate is set by the clinician and determines the net fluid removal.
• Risk Factors (for requiring CRRT): These are the conditions leading to severe AKI or fluid overload that necessitate CRRT:
  • Severe Acute Kidney Injury (AKI): Particularly Stage 3 AKI (KDIGO criteria: creatinine >3 times baseline, or creatinine >4.0 mg/dL with acute rise of >=0.3 mg/dL, or anuria/oliguria for >12 hours).
  • Fluid Overload (refractory to diuretics): Leading to pulmonary edema, respiratory failure, or significant peripheral edema compromising organ function.
  • Severe Electrolyte Imbalances: Refractory hyperkalemia (K+ >6.5 mEq/L, especially with ECG changes), severe metabolic acidosis (pH <7.1) refractory to medical management, severe hypernatremia or hyponatremia.
  • Uremic Complications: Uremic encephalopathy, pericarditis, neuropathy, coagulopathy.
  • Poisonings/Drug Overdoses: Removal of dialyzable toxins (e.g., salicylates, lithium, some alcohols) when conventional methods fail or are too slow.
  • Sepsis/Septic Shock: Often associated with AKI, MODS, and profound hemodynamic instability, making CRRT a safer option than IHD.
  • Cardiogenic Shock: Especially with significant fluid overload where intermittent therapy might exacerbate hemodynamic compromise.
• Protective Factors: Not directly applicable to CRRT itself as it is a treatment modality for established severe illness. However, prevention of AKI and timely management of underlying critical illness can reduce the need for CRRT:
  • Maintaining adequate hemodynamics and perfusion.
  • Avoiding nephrotoxic medications when possible or adjusting doses.
  • Early recognition and management of sepsis or shock.
  • Optimizing fluid balance in at-risk patients.

Clinical Presentation (Indications for CRRT)

Signs and Symptoms

CRRT is indicated for specific, severe manifestations of renal failure or fluid overload in critically ill patients. The signs and symptoms are those of the underlying condition. The "AEIOU" mnemonic is commonly used for general RRT indications: - Cardinal Features: * Acidosis: Severe metabolic acidosis (pH <7.1) refractory to medical therapy (e.g., bicarbonate). * Electrolyte abnormalities: Refractory hyperkalemia (K+ >6.5 mEq/L or with ECG changes like peaked T waves, widened QRS, sine wave), severe hypernatremia/hyponatremia, hypermagnesemia, hyperphosphatemia. * Intoxications: Dialyzable poisons or drugs (e.g., salicylates, lithium, methanol, ethylene glycol, phenobarbital). * Overload (fluid): Severe volume overload refractory to diuretics, leading to pulmonary edema, respiratory distress, or severe peripheral edema. * Uremia: Uremic encephalopathy (altered mental status, seizures, coma), uremic pericarditis, uremic coagulopathy, severe intractable nausea/vomiting. - Early Signs: Oliguria (<0.5 mL/kg/hr for >6-12 hours) or anuria, rising serum creatinine and BUN, mild electrolyte derangements (e.g., K+ 5.5-6.0 mEq/L), mild fluid retention. These may indicate developing AKI but not necessarily immediate CRRT need. - Advanced Signs: Persistent anuria, severe dyspnea from pulmonary edema, altered mental status, cardiac arrhythmias (due to hyperkalemia), Kussmaul respirations (due to metabolic acidosis). These are the direct indications for CRRT. - Atypical Presentations: Certain systemic conditions may benefit from CRRT even without typical AKI indications, such as severe sepsis with refractory shock, severe rhabdomyolysis, or tumor lysis syndrome where high solute load requires efficient removal.

Physical Examination

Findings reflect the underlying severe organ dysfunction leading to CRRT. - Inspection: * Respiratory distress: Tachypnea, increased work of breathing, use of accessory muscles, orthopnea (due to pulmonary edema). * Edema: Peripheral, sacral, periorbital edema; anasarca. * Neurological: Altered mental status (lethargy, confusion, delirium, stupor, coma), asterixis (uremic encephalopathy). * Skin: Uremic frost (rare). - Palpation: * Pitting edema: Indicating significant fluid overload. * Pericardial friction rub: Suggestive of uremic pericarditis. * Pulses: May be bounding if hypervolemic, or weak/thready if in shock. - Special Tests: Not specific for the need for CRRT but may be used to assess the underlying condition: * Cardiac auscultation: S3 gallop, crackles (rales) over lung fields (pulmonary edema), diminished heart sounds (pericardial effusion). * Neurological exam: Assessment of level of consciousness, motor responses, reflexes.

Diagnostic Approach

History Taking

• Key Questions:
  • Onset and Progression of Symptoms: How quickly did oliguria/anuria develop? What are the associated symptoms (dyspnea, altered mental status)?
  • Underlying Medical Conditions: History of CKD, heart failure, liver disease, diabetes, hypertension, malignancy, sepsis.
  • Recent Events: Sepsis, major surgery, trauma, burns, severe dehydration, cardiogenic shock.
  • Medication History: Recent use of nephrotoxic drugs (NSAIDs, ACE inhibitors, ARBs, certain antibiotics, contrast media), diuretics.
  • Fluid Intake/Output: Estimation of recent fluid balance.
  • Exposure to Toxins: Potential ingestions, occupational exposures.
  • Previous RRT: History of dialysis.
• Red Flags:
  • Acute onset anuria or severe oliguria.
  • Rapidly increasing creatinine and BUN.
  • New-onset altered mental status or seizures in a patient with kidney injury.
  • Severe dyspnea not explained by other causes.
  • ECG changes suggestive of hyperkalemia.

Laboratory Tests

• First-Line:
  • Complete Metabolic Panel (CMP): Serum creatinine, BUN (to assess kidney function and degree of uremia), electrolytes (Na, K, Cl, HCO3, Ca, Phos, Mg), glucose, liver function tests.
  • Arterial Blood Gas (ABG): To assess pH, PaCO2, PaO2, and calculate bicarbonate for acid-base status.
  • Complete Blood Count (CBC): To check for anemia (common in CKD), thrombocytopenia, leukocytosis (infection).
  • Lactate: Marker of tissue hypoperfusion/shock.
• Confirmatory: The "confirmation" for CRRT need is clinical and biochemical severity, not a specific single test. The tests below help confirm the severity and monitor the effects of CRRT.
  • Creatinine Kinase (CK) and Urine Myoglobin: If rhabdomyolysis is suspected.
  • Osmolal Gap: If toxic alcohol ingestion is suspected (methanol, ethylene glycol).
  • Drug Levels: If specific drug overdose is suspected (e.g., salicylates, lithium, phenobarbital).
  • Urine Studies: Urinalysis, urine sodium, urine creatinine, fractional excretion of sodium (FENa), fractional excretion of urea (FEUrea) to differentiate pre-renal, intrinsic, or post-renal AKI.
• Monitoring (during CRRT):
  • Daily or more frequent electrolytes: Na, K, Cl, HCO3, Ca, Phos, Mg (Q6-12h initially, then Q12-24h once stable).
  • BUN/Creatinine: To assess clearance and resolution of AKI.
  • ABG/Venous Blood Gas (VBG): To monitor acid-base status.
  • Ionized Calcium (iCa): Crucial for patients on regional citrate anticoagulation (monitor pre-filter, post-filter, and systemic iCa).
  • Coagulation Profile (PT/INR, aPTT): For patients on systemic anticoagulation.
  • Fibrinogen, Platelets: To monitor for bleeding/clotting issues.

Imaging

• Recommended:
  • Renal Ultrasound with Doppler: First-line imaging for AKI to assess kidney size, look for hydronephrosis (obstruction), and evaluate renal blood flow. Useful in identifying chronic kidney disease (small, echogenic kidneys).
  • Chest X-ray (CXR): To assess for pulmonary edema, pleural effusions, or other pulmonary complications from fluid overload or underlying disease.
• Advanced:
  • CT Abdomen/Pelvis: If renal calculi, mass, or retroperitoneal pathology is suspected as the cause of AKI.
  • Echocardiogram: To assess cardiac function, volume status, and rule out pericardial effusion in uremic pericarditis.

Management

Acute Management (CRRT Initiation)

• Immediate (Pre-initiation):
  • Vascular Access: Secure placement of a dual-lumen, large-bore central venous catheter (minimum 12-13.5 Fr) in a major vein (internal jugular, femoral, or subclavian). Femoral is often preferred in emergencies due to ease and safety, but IJ or subclavian may be used for long-term access if patient stabilizes.
  • Patient Stabilization: Address life-threatening electrolyte abnormalities (e.g., IV calcium gluconate for hyperkalemia with ECG changes), administer initial bicarbonate boluses for severe acidosis, prepare for intubation if respiratory compromise is severe.
  • CRRT Machine Setup: Prime the CRRT circuit with crystalloid or albumin-containing solution, ensure all lines are connected correctly, and prepare replacement fluids and dialysate.
• Stabilization (Initial CRRT Prescription):
  • Mode Selection: CVVHDF is often the default due to combined efficiency; CVVH if convection is preferred (e.g., for middle molecule removal); CVVHD if diffusion is preferred (e.g., small molecule removal, specific intoxications); SCUF for fluid removal only.
  • Blood Flow Rate (BFR): Typically initiated at 100-150 mL/min, then titrated up to 150-200 mL/min to maximize filter efficiency and maintain adequate blood flow without excessive shear stress.
  • Effluent Dose:
    • Standard Dose: 20-25 mL/kg/hr of total effluent (dialysate + replacement fluid + net ultrafiltrate). This dose is generally considered adequate for optimal solute clearance in AKI without conferring additional survival benefit from higher doses. (KDIGO guideline: 20-25 mL/kg/hr).
    • Higher Doses: May be considered for specific situations like severe intoxications or hypercatabolic states, but generally not routinely recommended for AKI.
  • Anticoagulation:
    • Regional Citrate Anticoagulation (RCA): Preferred method for most patients without contraindications (e.g., severe liver failure, lactic acidosis) due to lower bleeding risk. Citrate chelates calcium in the circuit, preventing clotting. Infusion targets a post-filter ionized calcium (iCa) of 0.25-0.35 mmol/L. Systemic calcium replacement is required to prevent hypocalcemia (target systemic iCa 1.1-1.25 mmol/L).
    • Unfractionated Heparin (UFH): Common alternative. Initial bolus (e.g., 1000-2000 units) followed by continuous infusion (e.g., 5-15 units/kg/hr) into the circuit pre-filter. Monitor aPTT (target 1.5-2.0 times control or institutional protocol).
    • No Anticoagulation: May be considered in patients with high bleeding risk or active bleeding. Requires frequent flushing of the circuit and may lead to shorter filter life.
  • Fluid Balance: Prescribe desired net ultrafiltration rate (NUR) based on the patient's fluid overload and hemodynamic tolerance. Start cautiously (e.g., 0-100 mL/hr) and titrate based on clinical assessment (e.g., resolution of pulmonary edema, blood pressure response).
  • Electrolyte/Acid-Base Management: Choose appropriate dialysate and replacement fluids based on baseline labs. Adjust fluid composition as needed.
• Emergency: For immediately life-threatening conditions (e.g., severe hyperkalemia with arrhythmias, profound acidosis):
  • Rapid initiation of CRRT.
  • Consider higher initial effluent doses (e.g., 30-35 mL/kg/hr) for quicker solute removal, then de-escalate.
  • Ensure immediate availability of emergency medications (calcium gluconate/chloride, insulin/dextrose, bicarbonate, albuterol for hyperkalemia).

Chronic Management (Ongoing CRRT)

• Pharmacological:
  • Medication Dosing Adjustment: CRRT significantly alters the pharmacokinetics of many renally cleared drugs (antibiotics, sedatives, vasopressors). Drug dosages must be adjusted frequently based on CRRT parameters (effluent rate), drug properties (molecular weight, protein binding, volume of distribution), and patient response. Consult pharmacy or reference resources (e.g., Micromedex, Lexicomp) for specific guidance.
  • Electrolyte Replacement: Continuous monitoring and replacement of electrolytes (potassium, phosphate, magnesium, calcium) are essential as CRRT removes them.
• Non-pharmacological:
  • Nutrition: Critically ill patients on CRRT are highly catabolic. Early and adequate nutritional support (enteral preferred) is crucial, accounting for protein losses (10-15 g/day through CRRT). Target protein intake of 1.5-2.0 g/kg/day.
  • Infection Control: Strict aseptic technique for catheter care. Monitor for catheter-related bloodstream infections.
  • Skin Care: Prevent pressure ulcers due to prolonged immobility.
  • Psychological Support: For patients and families in the ICU setting.
• Monitoring (Ongoing):
  • Daily Laboratory Tests: Full electrolyte panel, BUN, creatinine, ABG/VBG, CBC, coagulation profile (as indicated by anticoagulation strategy). Ionized calcium levels must be meticulously monitored if on citrate.
  • Fluid Balance: Strict intake and output charting, daily weights. Adjust net ultrafiltration based on fluid status.
  • Hemodynamics: Continuous monitoring of blood pressure, heart rate, and central venous pressure (CVP) or other hemodynamic parameters.
  • CRRT Circuit: Monitor pressures (access, return, transmembrane pressure), filter clotting, air detection.
  • Clinical Status: Assess for improvement in AKI symptoms (mentation, respiratory status, urine output if recovering).

Treatment Algorithms

• First-Line (General Approach):
  1. Assess Indications: Does the patient meet "AEIOU" or other severe indications for RRT?
  2. Evaluate Hemodynamic Stability: If unstable, CRRT is preferred over IHD.
  3. Vascular Access: Place appropriate central venous catheter.
  4. Mode Selection: CVVHDF for broad clearance, CVVH for middle molecule, CVVHD for small molecule. SCUF for fluid only.
  5. Prescription:
     • BFR: 150-200 mL/min.
     • Effluent Dose: 20-25 mL/kg/hr.
     • Anticoagulation: Regional Citrate preferred (target post-filter iCa 0.25-0.35 mmol/L, systemic iCa 1.1-1.25 mmol/L); UFH (target aPTT 1.5-2.0x control) or no anticoagulation as alternatives.
     • Net Ultrafiltration: Titrate to achieve desired fluid balance (e.g., 0 to +200 mL/hr, then increasing to -50 to -200 mL/hr as tolerated to remove excess fluid).
  6. Continuous Monitoring & Adjustment: Frequent labs, vital signs, fluid balance. Adjust medication dosing.
• Second-Line (Adjustments for Specific Scenarios):
  • Refractory Hyperkalemia: Increase potassium removal by increasing effluent dose, increasing dialysate potassium if hypokalemia develops.
  • Severe Metabolic Acidosis: Adjust bicarbonate concentration in dialysate/replacement fluid. Increase effluent dose.
  • Hypothermia: Use a blood warmer on the CRRT machine.
  • Circuit Clotting: Re-evaluate anticoagulation strategy, BFR, and potential access issues. Consider increasing anticoagulation or switching to a different agent.
• Refractory Cases (CRRT Failures/Challenges):
  • Persistent Filter Clotting: Despite optimized anticoagulation, consider underlying coagulopathy, catheter malfunction, or severe hypercoagulable state. May require catheter repositioning or exchange.
  • Inadequate Solute Clearance: Increase effluent dose, maximize BFR, troubleshoot circuit issues (e.g., recirculation).
  • Persistent Hemodynamic Instability: Maximize vasopressor support, optimize fluid status, reassess underlying cause of shock. CRRT often helps stabilize hemodynamics by removing fluid and correcting electrolyte/acid-base.
  • Inability to Achieve Negative Fluid Balance: Maximize NUR within patient tolerance. Consider adjuncts like albumin infusion to pull fluid into vascular space.

Complications

• Common:
  • Hypotension: Most frequent complication, often due to aggressive fluid removal, vasodilation from the circuit, or underlying critical illness. Manage by reducing NUR, administering fluid boluses, or increasing vasopressor support.
  • Electrolyte Abnormalities: Hypokalemia, hypophosphatemia, hypomagnesemia, hypocalcemia (especially with citrate anticoagulation) are common due to continuous removal. Requires careful monitoring and repletion. Hypernatremia or hyponatremia can occur with inappropriate fluid selection.
  • Bleeding: Significant risk with systemic anticoagulation. Requires careful monitoring of coagulation parameters and signs of bleeding. Even with citrate, systemic bleeding risk is present due to baseline coagulopathy in critically ill.
  • Circuit Clotting: Leading to premature filter failure and loss of therapy. Common causes include inadequate anticoagulation, low blood flow, or catheter issues.
  • Catheter-Related Complications: Malposition, mechanical dysfunction, infection (catheter-related bloodstream infection, CRBSI).
  • Hypothermia: Due to extracorporeal circulation; preventable with blood warmers.
• Serious:
  • Air Embolism: Rare but potentially fatal, due to air entering the circuit and being pumped to the patient. Rigorous attention to line connections and air detection systems is crucial.
  • Hemorrhage: Severe bleeding, potentially life-threatening, especially in patients already coagulopathic.
  • Severe Electrolyte Shifts: Rapid shifts (e.g., rapid correction of hyponatremia or hypernatremia) can cause osmotic demyelination syndrome or cerebral edema.
  • Dialysis Disequilibrium Syndrome (DDS): Rare with CRRT due to slow solute removal, but can occur if very rapid solute clearance causes osmotic fluid shift into brain cells, leading to cerebral edema, headache, nausea, seizures, or coma. More common with IHD.
• Long-term:
  • Prolonged ICU Stay: Patients requiring CRRT are generally very ill, leading to extended hospitalizations.
  • Increased Risk of Chronic Kidney Disease (CKD): Many survivors of severe AKI requiring CRRT do not fully recover kidney function and may progress to CKD or end-stage renal disease (ESRD), requiring long-term dialysis or transplant.
  • Nutritional Deficiencies: Due to prolonged catabolism and nutrient loss in the ultrafiltrate.
  • Muscle Weakness/Critical Illness Neuromyopathy: Common in prolonged critical illness.

Prognosis

• Factors:
  • Severity of Underlying Illness: Most critical determinant. Patients with multi-organ failure, severe sepsis, or refractory shock have significantly worse prognosis. SOFA score, APACHE II score are predictive.
  • Etiology of AKI: AKI due to sepsis carries a higher mortality than that due to nephrotoxins.
  • Timing of CRRT Initiation: Early initiation (before severe acidosis or fluid overload) may improve outcomes for certain patients, but the optimal timing remains a debated topic.
  • Age and Comorbidities: Advanced age, pre-existing CKD, heart failure, liver disease, or malignancy worsen prognosis.
  • Renal Recovery: Patients who recover kidney function have better long-term outcomes than those who remain dialysis-dependent.
• Survival:
  • Hospital mortality rates for critically ill patients requiring CRRT are high, ranging from 40% to 60%, reflecting the severity of their underlying conditions rather than CRRT itself.
  • Survival to discharge is typically 40-50%.
  • Long-term survival after discharge is also significantly lower than age-matched general population.
• Quality of Life:
  • For survivors, quality of life can be significantly impacted, especially if they remain dialysis-dependent.
  • Persistent physical and cognitive impairments are common due to critical illness-associated weakness and neurological sequelae.
  • Many patients experience post-intensive care syndrome (PICS).

Prevention

• Primary (Preventing initial occurrence of severe AKI requiring RRT):
  • Hemodynamic Optimization: Maintain adequate mean arterial pressure (MAP >65 mmHg) and cardiac output to ensure renal perfusion.
  • Avoidance of Nephrotoxins: Judicious use and appropriate dosing of nephrotoxic drugs (NSAIDs, aminoglycosides, contrast agents).
  • Fluid Management: Avoid both dehydration and excessive fluid overload in at-risk patients.
  • Early Sepsis Management: Prompt recognition and aggressive management of sepsis.
• Secondary (Early detection and intervention to prevent progression):
  • AKI Screening: Regular monitoring of creatinine and urine output in at-risk patients (e.g., ICU patients, post-surgery).
  • KDIGO AKI Stages: Implement strategies based on KDIGO AKI staging (e.g., avoiding nephrotoxins, fluid optimization for Stage 1-2 AKI) to prevent progression to Stage 3.
• Tertiary (Preventing complications while on CRRT and optimizing recovery):
  • Strict Adherence to Protocols: For CRRT setup, monitoring, and anticoagulation.
  • Infection Prevention: Aseptic catheter insertion and maintenance.
  • Nutritional Support: Early and adequate enteral nutrition.
  • Electrolyte Management: Meticulous monitoring and replacement.
  • Physical Therapy: Early mobilization and rehabilitation to mitigate ICU-acquired weakness.
  • Renal Recovery Monitoring: Assess for spontaneous kidney function recovery to guide discontinuation of CRRT.

Special Populations

• Pediatric:
  • Access: Smaller catheter sizes (e.g., 6.5-8 Fr) and different insertion sites may be required.
  • Circuit Volume: Smaller blood prime volumes are critical to prevent significant blood loss and hemodynamic instability.
  • Fluid Balance: Extremely precise fluid management due to smaller body size and higher susceptibility to fluid shifts.
  • Dosing: Effluent doses are typically weight-based, similar to adults (20-35 mL/kg/hr).
  • Anticoagulation: Regional citrate is also preferred in pediatrics due to lower bleeding risk.
• Geriatric:
  • Increased Vulnerability: Elderly patients are more susceptible to AKI due to lower baseline GFR, comorbidities, and polypharmacy.
  • Comorbidities: Higher prevalence of heart failure, diabetes, and CKD, complicating fluid and electrolyte management.
  • Frailty: Increased risk of complications (e.g., muscle weakness, delirium) and poorer long-term functional outcomes. Careful fluid management and slower rates of solute removal may be beneficial.
• Pregnancy:
  • Limited Data: CRRT in pregnancy is rare and data is limited.
  • Specific Indications: Severe AKI secondary to preeclampsia/eclampsia, HELLP syndrome, or septic abortion.
  • Fetal Monitoring: Fetal well-being must be closely monitored. Decisions are complex and require multidisciplinary input (nephrology, maternal-fetal medicine).
  • Drug Dosing: Special considerations for renally cleared drugs affecting the fetus.
• Comorbidities:
  • Sepsis/Septic Shock: CRRT is often preferred due to hemodynamic instability. May help remove inflammatory mediators, but evidence on this "immunomodulatory" effect is controversial.
  • Cardiogenic Shock: CRRT is favored due to better hemodynamic tolerance and ability to precisely manage fluid overload without rapid shifts.
  • Liver Failure: Caution with regional citrate due to impaired citrate metabolism, increasing risk of citrate accumulation and metabolic acidosis/hypocalcemia. Unfractionated heparin or no anticoagulation may be preferred.
  • Trauma/Burns: High catabolic states and fluid shifts. CRRT can help manage high solute load and complex fluid balance.

Clinical Pearls

• Diagnostic:
  • Always consider "AEIOU" as indications for RRT, with a strong emphasis on the refractory nature of the derangements.
  • Fluid overload is often underestimated clinically; daily weights and strict input/output are crucial.
  • Don't wait for "crash and burn" scenarios; consider early CRRT initiation in patients with rapidly progressing, severe AKI in the context of hemodynamic instability.
• Treatment:
  • CRRT is a supportive therapy, not a cure for AKI. Focus on treating the underlying cause.
  • Anticoagulation with regional citrate is generally preferred when not contraindicated due to lower systemic bleeding risk. Be meticulous with calcium monitoring and replacement.
  • The "dose" of CRRT (effluent rate) is critical for adequate solute clearance. 20-25 mL/kg/hr is the standard target. Higher doses have not shown survival benefit and may increase complications.
  • Fluid balance is paramount. Titrate net ultrafiltration carefully to avoid hypotension and optimize volume status.
  • Drug dosing adjustments are mandatory. Consult pharmacy or reliable pharmacokinetic resources for every renally cleared medication.
  • Nutritional support is vital. Patients on CRRT are highly catabolic.
• Pitfalls:
  • Underestimating fluid overload or electrolyte disturbances: Leading to delayed initiation or inadequate therapy.
  • Inadequate anticoagulation: Resulting in frequent filter clotting and interruptions to therapy.
  • Over-anticoagulation: Causing severe bleeding.
  • Failure to adjust medication doses: Leading to drug accumulation and toxicity or subtherapeutic levels.
  • Neglecting patient's overall critical illness: Focusing solely on kidney parameters while missing other organ system failures.
  • Poor vascular access management: Leading to catheter dysfunction, infection, or poor blood flow.

Recent Updates

• Guidelines:
  • KDIGO (Kidney Disease: Improving Global Outcomes) 2012 AKI Guideline: Remains the cornerstone, recommending an RRT dose of 20-25 mL/kg/hr. It emphasizes prompt recognition of AKI and considers RRT when fluid overload, hyperkalemia, metabolic acidosis, or uremic complications are present and refractory to medical therapy.
  • ESICM (European Society of Intensive Care Medicine) Guidelines on AKI (2022 Update in process): Continually refines recommendations on timing, dose, and anticoagulation strategies.
• Evidence:
  • Timing of Initiation: Several large randomized controlled trials (e.g., AKIKI, ELAIN, STARRT-AKI) have explored early versus delayed initiation of RRT in AKI. Overall, these studies have not shown a survival benefit for early vs. delayed initiation in a broad unselected AKI population, though early initiation may be beneficial in specific patient subgroups (e.g., severe fluid overload). The current consensus favors initiating RRT when absolute indications are present.
  • CRRT Dose: Large trials (e.g., ATN, RENAL) consistently demonstrate that higher doses (>35 mL/kg/hr) do not improve mortality outcomes compared to standard doses (20-25 mL/kg/hr) but may increase costs and complications.
  • Anticoagulation: Regional citrate has increasingly become the preferred anticoagulation method due to its proven efficacy in prolonging filter life and significantly lower risk of bleeding compared to systemic heparin, especially in patients without severe liver dysfunction.
• Controversies:
  • Optimal Timing of RRT Initiation: While studies show no overall benefit for early initiation, defining "early" and selecting appropriate subgroups for potentially earlier intervention remains an area of active research.
  • Role of Biomarkers for AKI and RRT Initiation: Research is ongoing to identify novel biomarkers that could better predict AKI progression and guide the optimal timing of RRT initiation.
  • Immunomodulatory Effects of CRRT: While CRRT can remove cytokines and inflammatory mediators, definitive evidence that this improves outcomes in sepsis is lacking.
  • Prognosis and Withdrawal of CRRT: Ethical considerations around withdrawal of CRRT in patients with poor prognosis.

Key References

• Guidelines:
  • KDIGO Clinical Practice Guideline for Acute Kidney Injury (2012). Kidney International Supplements 2(1), 1–138.
  • KDIGO Clinical Practice Guidelines for AKI - 2022 Update (in progress/forthcoming)
• Studies:
  • ATN Study (Acute Renal Failure Trial Network). "Intensity of Renal Support in Critically Ill Patients with Acute Kidney Injury." N Engl J Med 2008; 359:7-20. (Compared intensive vs. less intensive RRT).
  • RENAL Study (The Randomized Evaluation of Normal vs. Augmented in Low-risk patients with Acute Renal Failure). "Intensity of Continuous Renal-Replacement Therapy in Critically Ill Patients." N Engl J Med 2009; 361:1627-1638. (Further supported standard dose CRRT).
  • AKIKI Study (Artificial Kidney Initiation in Kidney Injury). "Effect of Early vs Delayed Initiation of Renal Replacement Therapy on Mortality in Critically Ill Patients with Acute Kidney Injury: The AKIKI Randomized Clinical Trial." JAMA 2016; 316(3):293-302. (Early vs delayed initiation).
  • ELAIN Study (Early vs Late Initiation of Renal Replacement Therapy). "Effect of Early Initiation of Renal Replacement Therapy on Mortality in Critically Ill Patients with Acute Kidney Injury: A Randomized Clinical Trial." JAMA 2016; 316(3):303-312. (Early vs delayed initiation).
  • STARRT-AKI Study (Standard versus Accelerated Initiation of Renal Replacement Therapy in Acute Kidney Injury). "Timing of Initiation of Renal-Replacement Therapy in Acute Kidney Injury." N Engl J Med 2020; 383:240-251. (Further evidence on timing).
• Reviews:
  • Ronco C, Bellomo R, Kellum JA, Ricci Z. "Continuous Renal Replacement Therapy." Lancet 2015; 386(9999):260-269.
  • Hoste EAJ, Bellomo R, et al. "Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study." Intensive Care Med 2015; 41(8):1411-1423.
  • Gaudry S, et al. "Management of Acute Kidney Injury in Intensive Care Units." Chest 2022; 161(2):494-508.